Cargando…

The “Invisible Enemy” SARS-CoV-2: Viral Spread and Drug Treatment

Nowadays, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has become the main subject of the scientific medical world and all World Organizations, causing millions of deaths worldwide. In this review, we have highlighted the context of the Coronavirus disease 2019 (COVID-19) p...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanase, Alina, Manea, Aniko, Scurtu, Alexandra Denisa, Bratu, Lavinia Melania, Chioran, Doina, Dolghi, Alina, Alexoi, Iren, AAbed, Hazzaa, Lazureanu, Voichita, Dehelean, Cristina Adriana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875987/
https://www.ncbi.nlm.nih.gov/pubmed/35208584
http://dx.doi.org/10.3390/medicina58020261
_version_ 1784658061898547200
author Tanase, Alina
Manea, Aniko
Scurtu, Alexandra Denisa
Bratu, Lavinia Melania
Chioran, Doina
Dolghi, Alina
Alexoi, Iren
AAbed, Hazzaa
Lazureanu, Voichita
Dehelean, Cristina Adriana
author_facet Tanase, Alina
Manea, Aniko
Scurtu, Alexandra Denisa
Bratu, Lavinia Melania
Chioran, Doina
Dolghi, Alina
Alexoi, Iren
AAbed, Hazzaa
Lazureanu, Voichita
Dehelean, Cristina Adriana
author_sort Tanase, Alina
collection PubMed
description Nowadays, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has become the main subject of the scientific medical world and all World Organizations, causing millions of deaths worldwide. In this review, we have highlighted the context of the Coronavirus disease 2019 (COVID-19) pandemic, how the virus spreads, the symptoms and complications that may occur, and, especially, the drug treatment of viral infection, with emphasis on monoclonal antibodies. While well-known strains such as Alpha, Beta, Gamma, and, especially, Delta have shown an accelerated transmission among the population, the new Omicron variant (discovered on 24 November 2021) indicates more significant infectiousness and the poor efficacy of monoclonal antibody therapy due to mutations on the spike protein receptor-binding domain. With these discoveries, the experiments began, the first being in silico and in vitro, but these are not enough, and in vivo experiments are needed to see exactly the cause of neutralization of the action of these drugs. Following the documentation of the latest medical and scientific research, it has been concluded that there are many chemical molecules that have the potential to treat SARS-CoV-2 infection, but more detailed clinical trials are needed for their use in therapy. In addition, it is important to consider the structure of the viral strain in the administration of treatment.
format Online
Article
Text
id pubmed-8875987
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88759872022-02-26 The “Invisible Enemy” SARS-CoV-2: Viral Spread and Drug Treatment Tanase, Alina Manea, Aniko Scurtu, Alexandra Denisa Bratu, Lavinia Melania Chioran, Doina Dolghi, Alina Alexoi, Iren AAbed, Hazzaa Lazureanu, Voichita Dehelean, Cristina Adriana Medicina (Kaunas) Review Nowadays, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has become the main subject of the scientific medical world and all World Organizations, causing millions of deaths worldwide. In this review, we have highlighted the context of the Coronavirus disease 2019 (COVID-19) pandemic, how the virus spreads, the symptoms and complications that may occur, and, especially, the drug treatment of viral infection, with emphasis on monoclonal antibodies. While well-known strains such as Alpha, Beta, Gamma, and, especially, Delta have shown an accelerated transmission among the population, the new Omicron variant (discovered on 24 November 2021) indicates more significant infectiousness and the poor efficacy of monoclonal antibody therapy due to mutations on the spike protein receptor-binding domain. With these discoveries, the experiments began, the first being in silico and in vitro, but these are not enough, and in vivo experiments are needed to see exactly the cause of neutralization of the action of these drugs. Following the documentation of the latest medical and scientific research, it has been concluded that there are many chemical molecules that have the potential to treat SARS-CoV-2 infection, but more detailed clinical trials are needed for their use in therapy. In addition, it is important to consider the structure of the viral strain in the administration of treatment. MDPI 2022-02-10 /pmc/articles/PMC8875987/ /pubmed/35208584 http://dx.doi.org/10.3390/medicina58020261 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Tanase, Alina
Manea, Aniko
Scurtu, Alexandra Denisa
Bratu, Lavinia Melania
Chioran, Doina
Dolghi, Alina
Alexoi, Iren
AAbed, Hazzaa
Lazureanu, Voichita
Dehelean, Cristina Adriana
The “Invisible Enemy” SARS-CoV-2: Viral Spread and Drug Treatment
title The “Invisible Enemy” SARS-CoV-2: Viral Spread and Drug Treatment
title_full The “Invisible Enemy” SARS-CoV-2: Viral Spread and Drug Treatment
title_fullStr The “Invisible Enemy” SARS-CoV-2: Viral Spread and Drug Treatment
title_full_unstemmed The “Invisible Enemy” SARS-CoV-2: Viral Spread and Drug Treatment
title_short The “Invisible Enemy” SARS-CoV-2: Viral Spread and Drug Treatment
title_sort “invisible enemy” sars-cov-2: viral spread and drug treatment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875987/
https://www.ncbi.nlm.nih.gov/pubmed/35208584
http://dx.doi.org/10.3390/medicina58020261
work_keys_str_mv AT tanasealina theinvisibleenemysarscov2viralspreadanddrugtreatment
AT maneaaniko theinvisibleenemysarscov2viralspreadanddrugtreatment
AT scurtualexandradenisa theinvisibleenemysarscov2viralspreadanddrugtreatment
AT bratulaviniamelania theinvisibleenemysarscov2viralspreadanddrugtreatment
AT chiorandoina theinvisibleenemysarscov2viralspreadanddrugtreatment
AT dolghialina theinvisibleenemysarscov2viralspreadanddrugtreatment
AT alexoiiren theinvisibleenemysarscov2viralspreadanddrugtreatment
AT aabedhazzaa theinvisibleenemysarscov2viralspreadanddrugtreatment
AT lazureanuvoichita theinvisibleenemysarscov2viralspreadanddrugtreatment
AT deheleancristinaadriana theinvisibleenemysarscov2viralspreadanddrugtreatment
AT tanasealina invisibleenemysarscov2viralspreadanddrugtreatment
AT maneaaniko invisibleenemysarscov2viralspreadanddrugtreatment
AT scurtualexandradenisa invisibleenemysarscov2viralspreadanddrugtreatment
AT bratulaviniamelania invisibleenemysarscov2viralspreadanddrugtreatment
AT chiorandoina invisibleenemysarscov2viralspreadanddrugtreatment
AT dolghialina invisibleenemysarscov2viralspreadanddrugtreatment
AT alexoiiren invisibleenemysarscov2viralspreadanddrugtreatment
AT aabedhazzaa invisibleenemysarscov2viralspreadanddrugtreatment
AT lazureanuvoichita invisibleenemysarscov2viralspreadanddrugtreatment
AT deheleancristinaadriana invisibleenemysarscov2viralspreadanddrugtreatment